MAPT and Alzheimer disease: With this systematic review and meta-analysis, we aimed to report a pooled analysis and evidence of monoclonal antibodies lecanemab on clinical outcomes of cognitive function, biomarkers related to Aβ and tau pathologies, and the risk for adverse events associated with this drug class and ARIA in patients with AD.